Nivolumab Receives New Indication for dMMR and MSI-H Metastatic Colorectal Cancer

JHOP Web Exclusives - FDA Approvals, News & Updates, Online Only

On July 31, 2017, the FDA accelerated the approval of a new indication for nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of patients aged ≥12 years with mismatch repair–deficient (dMMR) and microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC) that progressed after treatment with fluoropyrimidine, oxaliplatin, and irinotecan.

The FDA approval of this new indication was based on a single-arm, open-label, multicenter clinical trial of 53 patients with locally determined dMMR or MSI-H metastatic CRC whose disease progressed during or after, or who could not tolerate, fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. All patients had received ≥1 treatments containing 1 of the 3 therapies. In the study leading to this approval, the patients received intravenous nivolumab 3 mg/kg every 2 weeks until unacceptable toxicity or radiographic progression.

The objective response rate was 28% (N = 15); of these 15 responses, 1 was a complete response and 14 were partial responses. In 67% of patients, the responses lasted ≥6 months. Among the 74 patients in the overall population, there was an objective response rate of 32%.

The study did not include a pediatric population; nivolumab’s dosing is 240 mg every 2 weeks in patients aged ≥12 years with MSI-H or dMMR metastatic CRC, which was determined based on results in adults.

The most common (≥20%) adverse events seen with nivolumab monotherapy include fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, and pyrexia. As a condition of the accelerated approval of this indication, further trials must confirm the clinical benefit of nivolumab in this setting

Related Items
February 8, 2019 - FDA Approvals, News & Updates
In the News: Oncology - January 2019 published on February 1, 2019 in Breaking News, FDA Approvals, News & Updates
February 1, 2019 - FDA Approvals, News & Updates
In the News: Oncology - January 2019 published on February 1, 2019 in Breaking News, FDA Approvals, News & Updates
I. New Drugs
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in FDA Approvals, News & Updates
II. New Indications
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in FDA Approvals, News & Updates
Government Shutdown Impacts FDA Drug Approvals
In the News: Oncology - February 2019 published on January 14, 2019 in Breaking News, FDA Approvals, News & Updates
Braftovi Plus Mektovi a New Combination for Unresectable or Metastatic Melanoma with BRAF Mutation
JHOP Web Exclusives published on November 30, 2018 in FDA Approvals, News & Updates
Lenvima Now Approved for Unresectable Hepatocellular Carcinoma
JHOP Web Exclusives published on November 13, 2018 in FDA Approvals, News & Updates
FDA News - September 2018
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in FDA Approvals, News & Updates
A Dynamic FDA Has Led to More Rapid Cancer Drug Development
Wayne Kuznar
JHOP Web Exclusives published on July 17, 2018 in FDA Approvals, News & Updates, In the News, Online Only
Welcome to the Third Annual Oncology Guide to New FDA Approvals
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates
Last modified: October 30, 2017